Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
RESEARCH TOOLSreports
Holding PTGX?
Track your performance easily
PTGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.78 - $48.89
Previous Close$45.9
Volume1.08M
Average Volume (3M)605.52K
Market Cap
$2.75B
Enterprise Value$2.20B
Total Cash (Recent Filing)$564.04M
Total Debt (Recent Filing)$10.97M
Price to Earnings (P/E)17.5
Beta0.33
Next Earnings
Mar 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.63
Shares Outstanding58,904,585
10 Day Avg. Volume470,608
30 Day Avg. Volume605,525
Standard Deviation0.29
R-Squared0.15
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)5.18
Price to Sales (P/S)8.47
Price to Cash Flow (P/CF)2.50
P/FCF Ratio2.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.90
Enterprise Value/Gross Profit36.69
Enterprise Value/Ebitda13.11
Forecast
1Y Price Target
$57.67Price Target Upside21.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Protagonist Therapeutics News
PremiumCompany Announcements
Protagonist Therapeutics Reports Strong Financial Turnaround
PremiumCompany Announcements
Protagonist Therapeutics Board and Audit Committee ChangesBulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyJNJ-2113's Phase 2b PsO data show efficacy better than any available oral therapy and equivalent to injectables, indicating a high probability of success for the four Phase 3 studies.
Market OpportunitiesRusfertide for Polycythemia Vera (PV) represents a $2 billion market opportunity, with promising Phase 2 data showing strong clinical benefit and attracting a collaboration with Takeda with a $300 million upfront payment.
Partnerships And Financial PotentialJNJ-2113 is an oral IL-23 receptor inhibitor co-developed with J&J in an agreement worth $967.5MM of milestones, plus 6-10% royalties.
Bears Say
Clinical Trial RisksRisks include unexpected safety concerns in ongoing clinical trials, partner JNJ potentially not pursuing JNJ-2113, and increased regulatory, competitive, and pricing risks.
Conflict Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Operational Expenditure2Q24 OpEx of $42M was below consensus/Citizens JMPe of $48M/$50M.
---
Ownership Overview
1.42% Insiders
14.38% Mutual Funds
0.86% Other Institutional Investors
55.48% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $14.78 and its highest was $48.89 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Currently, no data Available
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Mar 18, 2025 which is in 128 days.
How were Protagonist Therapeutics’s earnings last quarter?
Currently, no data Available
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 58,904,587 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Among the largest hedge funds holding Protagonist Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Protagonist Therapeutics’s shares valued at 202M.
---
Protagonist Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.67 (21.16% Upside)
$57.67 (21.16% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 531.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $631.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
192.20%
12-Months-Change
Fundamentals
Return on Equity
40.69%
Trailing 12-Months
Asset Growth
91.79%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
---
PTGX Stock 12 Month Forecast
Average Price Target
$57.67
▲(21.16% Upside)
Technical Analysis
Best Analysts Covering PTGX
1 Year
1 Year Success Rate
18/18 ratings generated profit
1 Year Average Return
+86.17%
reiterated a buy rating 3 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +86.17% per trade.
---